was read the article
array:23 [ "pii" => "S1578219019302070" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.03.022" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2201" "copyrightAnyo" => "2019" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2019;110:520" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731019301590" "issn" => "00017310" "doi" => "10.1016/j.ad.2019.03.009" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2201" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2019;110:520" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 191 "formatos" => array:2 [ "HTML" => 135 "PDF" => 56 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>" "titulo" => "Ixekizumab y psoriasis, ¿qué sucede en el mundo real?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "520" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ixekizumab and Psoriasis in the Real World" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "I. Belinchón Romero" "autores" => array:1 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "Belinchón Romero" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219019302070" "doi" => "10.1016/j.adengl.2019.03.022" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302070?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301590?idApp=UINPBA000044" "url" => "/00017310/0000011000000007/v1_201909021023/S0001731019301590/v1_201909021023/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219019301957" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.08.001" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2087" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Dermosifiliogr. 2019;110:521-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Evaluation of Sexual Life and Marital Satisfaction in Patients with Anogenital Wart" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "521" "paginaFinal" => "525" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evaluación de la vida sexual y de la satisfacción matrimonial en pacientes con verruga anogenital" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Nahidi, Y. Nahidi, G. Kardan, L. Jarahi, B. Aminzadeh, P. Shojaei, M.R. Fayyazi Bordbar" "autores" => array:7 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Nahidi" ] 1 => array:2 [ "nombre" => "Y." "apellidos" => "Nahidi" ] 2 => array:2 [ "nombre" => "G." "apellidos" => "Kardan" ] 3 => array:2 [ "nombre" => "L." "apellidos" => "Jarahi" ] 4 => array:2 [ "nombre" => "B." "apellidos" => "Aminzadeh" ] 5 => array:2 [ "nombre" => "P." "apellidos" => "Shojaei" ] 6 => array:2 [ "nombre" => "M.R. Fayyazi" "apellidos" => "Bordbar" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018304848" "doi" => "10.1016/j.ad.2018.08.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018304848?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019301957?idApp=UINPBA000044" "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019301957/v1_201909021030/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219019302094" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.05.014" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "2228" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2019;110:518-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>" "titulo" => "Patient-Reported Outcomes in Psoriasis Validated in Spain: PROs and Cons" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "518" "paginaFinal" => "519" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Patient reported outcomes en psoriasis validados en España: PROs y contras" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Puig" "autores" => array:1 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Puig" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731019301930" "doi" => "10.1016/j.ad.2019.05.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301930?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302094?idApp=UINPBA000044" "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019302094/v1_201909021030/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Ixekizumab and Psoriasis in the Real World" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "520" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "I. Belinchón Romero" "autores" => array:1 [ 0 => array:3 [ "nombre" => "I." "apellidos" => "Belinchón Romero" "email" => array:1 [ 0 => "belinchon_isa@gva.es" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital General Universitario de Alicante-ISABIAL, Universidad Miguel Hernández, Alicante, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Ixekizumab and Psoriasis in the Real WorldIxekizumab y psoriasis, ¿qué sucede en el mundo real?" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Psoriasis is an autoimmune disease with a complex pathogenesis in which the interaction of immunologic, genetic, and environmental factors results in different clinical forms, as well as different response to treatments.</p><p id="par0010" class="elsevierStylePara elsevierViewall">In recent years, better understanding of the disease pathogenesis has enabled development of agents with new therapeutic targets, with excellent results in clinical trials, particularly in the case of moderate to severe forms of the disease. However, study of the treatment of psoriasis in clinical practice is necessary, as the patients included in clinical trials are not fully representative of those treated in this setting.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Ixekizumab is a humanized recombinant biologic agent that targets IL-17A and that was recently approved for the treatment of moderate to severe plaque psoriasis. The efficacy and safety of the agent has been assessed in randomized clinical trials, although there is limited data on its use in routine clinical practice.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In this issue, Magdaleno-Tapial et al.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> describe their study of the efficacy and safety of ixekizumab in patients with psoriasis in routine clinical practice in 2 hospitals in the Mediterranean region. This retrospective, observational study included 75 patients with moderate to severe psoriasis, some of whom had psoriasis in difficult-to-treat locations, and who received ixekizumab for a mean duration of 46 weeks. The authors demonstrated the efficacy and safety of the agent in routine clinical practice and, although this is not the first study in the clinical setting,<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">4,5</span></a> it is the second largest series to date, and confirms the efficacy findings of previous studies. In addition, this study describes the efficacy of ixekizumab in difficult-to-treat sites such as the scalp, genital area, or palmoplantar region. The safety data are similar to those reported both in clinical trials and in studies in a clinical setting.</p><p id="par0025" class="elsevierStylePara elsevierViewall">In summary, this study provides valuable information on the treatment with ixekizumab of patients with psoriasis vulgaris and psoriasis in difficult-to-treat sites in a clinical practice setting. Nevertheless, larger studies and registries of routine clinical practice will be needed to extend our knowledge in a real-world setting.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2019-03-18" "fechaAceptado" => "2019-03-19" "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Belinchón Romero I. Ixekizumab and Psoriasis in the Real World. Actas Dermosifiliogr. 2019;110:521.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Garcia-Doval" 1 => "G. Carretero" 2 => "F. Vanaclocha" 3 => "C. Ferrandiz" 4 => "E. Daudén" 5 => "J.L. Sánchez-Carazo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archdermatol.2011.2768" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2012" "volumen" => "148" "paginaInicial" => "463" "paginaFinal" => "470" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22508869" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Blauvelt" 1 => "M. Gooderham" 2 => "L. Iversen" 3 => "S. Ball" 4 => "L. Zhang" 5 => "N.O. Agada" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2017.06.153" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2017" "volumen" => "77" "paginaInicial" => "855" "paginaFinal" => "862" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28917383" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eficacia y seguridad de ixekizumab en la práctica clínica habitual: estudio retrospectivo bicéntrico" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Magdaleno-Tapial" 1 => "R. Carmena-Ramón" 2 => "C. Valenzuela-Oñate" 3 => "J.M. Ortiz-Salvador" 4 => "J. Sabater-Abad" 5 => "P. Hernández-Bel" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2019" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ixekizumab for treatment of moderate to severe plaque psoriasis: Real world clinical experience" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F. Diotallevi" 1 => "A. Campanati" 2 => "G. Radi" 3 => "E. Molinelli" 4 => "A. Offidani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.23736/S0392-0488.18.06094-7" "Revista" => array:2 [ "tituloSerie" => "G Ital Dermatol Venereol" "fecha" => "2018" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: A multicentre retrospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Deza" 1 => "J. Notario" 2 => "A. Lopez-Ferrer" 3 => "E. Vilarrasa" 4 => "M. Ferran" 5 => "E. del Alcazar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.15288" "Revista" => array:5 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2019" "volumen" => "33" "paginaInicial" => "553" "paginaFinal" => "5598" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011000000007/v1_201909021030/S1578219019302070/v1_201909021030/en/main.assets" "Apartado" => array:4 [ "identificador" => "66476" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Commentaries" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011000000007/v1_201909021030/S1578219019302070/v1_201909021030/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302070?idApp=UINPBA000044" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 7 | 4 | 11 |
2024 October | 68 | 31 | 99 |
2024 September | 68 | 24 | 92 |
2024 August | 88 | 49 | 137 |
2024 July | 72 | 38 | 110 |
2024 June | 69 | 28 | 97 |
2024 May | 67 | 31 | 98 |
2024 April | 55 | 24 | 79 |
2024 March | 56 | 26 | 82 |
2024 February | 43 | 33 | 76 |
2024 January | 39 | 32 | 71 |
2023 December | 38 | 20 | 58 |
2023 November | 51 | 33 | 84 |
2023 October | 46 | 22 | 68 |
2023 September | 36 | 30 | 66 |
2023 August | 21 | 12 | 33 |
2023 July | 50 | 35 | 85 |
2023 June | 34 | 20 | 54 |
2023 May | 31 | 24 | 55 |
2023 April | 28 | 13 | 41 |
2023 March | 31 | 19 | 50 |
2023 February | 27 | 22 | 49 |
2023 January | 25 | 24 | 49 |
2022 December | 38 | 46 | 84 |
2022 November | 26 | 32 | 58 |
2022 October | 22 | 18 | 40 |
2022 September | 15 | 49 | 64 |
2022 August | 19 | 33 | 52 |
2022 July | 18 | 39 | 57 |
2022 June | 17 | 32 | 49 |
2022 May | 30 | 32 | 62 |
2022 April | 30 | 43 | 73 |
2022 March | 39 | 45 | 84 |
2022 February | 29 | 24 | 53 |
2022 January | 30 | 36 | 66 |
2021 December | 29 | 35 | 64 |
2021 November | 26 | 42 | 68 |
2021 October | 35 | 48 | 83 |
2021 September | 26 | 36 | 62 |
2021 August | 24 | 24 | 48 |
2021 July | 33 | 19 | 52 |
2021 June | 30 | 19 | 49 |
2021 May | 36 | 37 | 73 |
2021 April | 77 | 29 | 106 |
2021 March | 47 | 20 | 67 |
2021 February | 64 | 30 | 94 |
2021 January | 49 | 19 | 68 |
2020 December | 34 | 17 | 51 |
2020 November | 29 | 20 | 49 |
2020 October | 28 | 7 | 35 |
2020 September | 31 | 10 | 41 |
2020 August | 34 | 13 | 47 |
2020 July | 22 | 14 | 36 |
2020 June | 32 | 37 | 69 |
2020 May | 28 | 10 | 38 |
2020 April | 21 | 15 | 36 |
2020 March | 26 | 17 | 43 |
2020 February | 6 | 6 | 12 |